Nyrada Programs

Nyrada is developing NYR-BI03, a small molecule first-in-class drug for neuroprotection and cardioprotection indications.

In February 2024, Nyrada announced preclinical stroke study results showing that NYR-BI03 achieved a statistically significant neuroprotective effect, rescuing 42% of brain tissue in the penumbra region of treated animals.

In October 2024, Nyrada announced the results of a preclinical coronary heart disease study which showed that NYR-BI03 provided an 86% cardioprotective effect following myocardial ischemic-reperfusion injury, a leading cause of tissue damage when blood flow is restored to the heart after injury.

In April 2025, Nyrada announced the results of a preclinical traumatic brain injury study, which showed that NYR-BI03 provided statistically significant (p = 0.043; ANOVA) neuroprotective effect following a penetrating traumatic brain injury. This study was undertaken in collaboration with the Walter Reed Army Institute of Research and UNSW Sydney.